RxDoctor Payments Data

Ioana Dumitru, MD

Cardiovascular Disease · Tampa, FLNPI 1801844089

Payments from drug & device makers

$74,126in general payments, 2019–2025

Across 165 payments — averaging $449.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$44K
  • American Regent$14K
  • Merck$12K
  • Abbott$2K
  • Novartis$900
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$110
  • plus $343 from 8 others

What the payments were for

  • Speaking & faculty fees$35,20074%
  • Travel & lodging$4,0759%
  • Food & beverage$7,94117%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed101$44,492
American Regent10$13,842
Merck9$12,091
Abbott32$2,348
Novartis1$900
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$110
Alnylam Pharmaceuticals Inc.2$77
Medtronic1$76
Cvrx, Inc.1$44
Pfizer2$38
Scpharmaceuticals Inc.1$35
AstraZeneca1$26
One Lambda, Inc.1$24
Bioventrix, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,126 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$74,243
Medicare patients
349
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan105$144,993
FarxigaDapagliflozin Propanediol100$111,908
EliquisApixaban51$58,115
Repatha SureclickEvolocumab54$53,239
JardianceEmpagliflozin21$34,682
OzempicSemaglutide22$21,999
Repatha PushtronexEvolocumab22$16,255
Praluent PenAlirocumab24$14,073
Sildenafil Citrate41$8,655
Tacrolimus63$6,492
Sirolimus14$4,176
Eplerenone25$3,056
Valganciclovir Hcl12$2,865
Enoxaparin Sodium41$2,495
Metoprolol Succinate83$1,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$900$144,993105 claims
AstraZenecaFarxiga$26$111,908100 claims
PfizerEliquis$38$58,11551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →